Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression

Journal of Experimental Medicine

Volumn 200, Issue 12, 2004, Pages 1581-1592

  Zhou, Gang ^a   Lu, Zhengbin ^b   McCadden, John D ^a   Levitsky, Hyam I ^a   Marson, Aimee L ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Immune tolerance; Immunoediting; Immunosurveillance; T lymphocyte; Tumor escape

Indexed keywords

CD4 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTIGENICITY; ARTICLE; BIOLOGICAL MODEL; CELL FUNCTION; CONTROLLED STUDY; IMMUNOSURVEILLANCE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR GROWTH;

ANIMALS; ANTIGENS, NEOPLASM; CARCINOMA; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; IMMUNE TOLERANCE; KIDNEY NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; TUMOR ESCAPE;

EID: 11844302141     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20041240     Document Type: Article

References (54)

1. Ehrlich, P. 1909. Ueber den jetzigen stand der Karzinomforschung. Ned. Tijdschr. Geneeskd. 5:273-290.
2. Thomas, L. 1959. Discussion for Reactions to homologous tissue antigens in relation to hypersensitivity. In Cellular and Humoral Aspects of the Hypersensitive States. H.S. Lawrence, editor. Hoeber-Harper, New York. 529-532.
3. Burnet, F.M. 1970. The concept of immunological surveillance. Progr. Exp. Tumor Res. 13:1-27.
4. Shankaran, V., H. Ikeda, A.T. Bruce, J.M. White, P.E. Swanson, L.J. Old, and R.D. Schreiber. 2001. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 410:1107-1111.
5. Dunn, G.P., A.T. Bruce, H. Ikeda, L.J. Old, and R.D. Schreiber. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3:991-998.
6. North, R.J. 1984. The therapeutic significance of concomitant antitumor immunity. I. LY-1- 2+ T cells from mice with a progressive tumor can cause regression of an established tumor in gamma-irradiated recipients. Cancer Immunol. Immunother. 18:69-74.
7. Lee, P.P., C. Yee, P.A. Savage, L. Fong, D. Brockstedt, J.S. Weber, D. Johnson, S. Swetter, J. Thompson, P.D. Greenberg, et al. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:677-685.
8. Bogen, B. 1996. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur. J. Immunol. 26:2671-2679.
9. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA. 95:1178-1183.
10. Sotomayor, E.M., I. Borrello, E. Tubb, F.M. Rattis, H. Bien, Z. Lu, S. Fein, S. Schoenberger, and H.I. Levitsky. 1999. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 5:780-787.
11. Sotomayor, E.M., I. Borrello, and H.I. Levitsky. 1996. Tolerance and cancer: a critical issue in tumor immunology. Crit. Rev. Oncog. 7:433-456.
12. + single positive cells with a class II major histocompatibility complex-restricted receptor. J. Exp. Med. 180:25-34.
13. Morgan, D.J., R. Liblau, B. Scott, S. Fleck, H.O. McDevitt, N. Sarvetnick, D. Lo, and L.A. Sherman. 1996. CD8(+) T cell-mediated spontaneous diabetes in neonatal mice. J. Immunol. 157:978-983.
14. Morgan, D.J., H.T. Kreuwel, S. Fleck, H.I. Levitsky, D.M. Pardoll, and L.A. Sherman. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160:643-651.
15. Lu, Z., L. Yuan, X. Zhou, E. Sotomayor, H.I. Levitsky, and D.M. Pardoll. 2000. CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J. Exp. Med. 191:541-550.
16. Cuenca, A., F. Cheng, H. Wang, J. Brayer, P. Horna, L. Gu, H. Bien, I.M. Borrello, H.I. Levitsky, and E.M. Sotomayor. 2003. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res. 63:9007-9015.
17. Dunn, G.P., L.J. Old, and R.D. Schreiber. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22:329-360.
18. Zhang, L., J.R. Conejo-Garcia, D. Katsaros, P.A. Gimotty, M. Massobrio, G. Regnani, A. Makrigiannakis, H. Gray, K. Schlienger, M.N. Liebman, et al. 2003. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348:203-213.
19. Seliger, B., T. Cabrera, F. Garrido, and S. Ferrone. 2002. HLA class I antigen abnormalities and immune escape by malignant cells. Semin. Cancer Biol. 12:3-13.
20. Speiser, D.E., R. Miranda, A. Zakarian, M.F. Bachmann, K. McKall-Faienza, B. Odermatt, D. Hanahan, R.M. Zinkernagel, and P.S. Ohashi. 1997. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186:645-653.
21. Ochsenbein, A.F., P. Klenerman, U. Karrer, B. Ludewig, M. Pericin, H. Hengartner, and R.M. Zinkernagel. 1999. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA. 96:2233-2238.
22. Nguyen, L.T., A.R. Elford, K. Murakami, K.M. Garza, S.P. Schoenberger, B. Odermatt, D.E. Speiser, and P.S. Ohashi. 2002. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J. Exp. Med. 195:423-435.
23. Marzo, A.L., B.F. Kinnear, R.A. Lake, J.J. Frelinger, E.J. Collins, B.W. Robinson, and B. Scott. 2000. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J. Immunol. 165:6047-6055.
24. Shrikant, P., and M.F. Mescher. 1999. Control of syngeneic tumor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. J. Immunol. 162:2858-2866.
25. Colella, T.A., T.N. Bullock, L.B. Russell, D.W. Mullins, W.W. Overwijk, C.J. Luckey, R.A. Pierce, N.P. Restifo, and V.H. Engelhard. 2000. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J. Exp. Med. 191:1221-1232.
26. Molldrem, J.J., P.P. Lee, S. Kant, E. Wieder, W. Jiang, S. Lu, C. Wang, and M.M. Davis. 2003. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest. 111:639-647.
27. Ochsenbein, A.F., S. Sierro, B. Odermatt, M. Pericin, U. Karrer, J. Hermans, S. Hemmi, H. Hengartner, and R.M. Zinkernagel. 2001. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature. 411:1058-1064.
28. Spiotto, M.T., P. Yu, D.A. Rowley, M.I. Nishimura, S.C. Meredith, T.F. Gajewski, Y.X. Fu, and H. Schreiber. 2002. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 17:737-747.
29. Groh, V., J. Wu, C. Yee, and T. Spies. 2002. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 419:734-738.
30. Wang, T., G. Niu, M. Kortylewski, L. Burdelya, K. Shain, S. Zhang, R. Bhattacharya, D. Gabrilovich, R. Heller, D. Coppola, et al. 2004. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10:48-54.
31. Cheng, F., H.W. Wang, A. Cuenca, M. Huang, T. Ghansah, J. Brayer, W.G. Kerr, K. Takeda, S. Akira, S.P. Schoenberger, et al. 2003. A critical role for Stat3 signaling in immune tolerance. Immunity. 19:425-436.
32. Gorelik, L., and R.A. Flavell. 2001. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. 7:1118-1122.
33. Gabrilovich, D.I., H.L. Chen, K.R. Girgis, H.T. Cunningham, G.M. Meny, S. Nadaf, D. Kavanaugh, and D.P. Carbone. 1996. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2:1096-1103 (published erratum appears in Nat. Med. 1996. 2:1267).
34. Melcher, A., S. Todryk, N. Hardwick, M. Ford, M. Jacobson, and R.G. Vile. 1998. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med. 4:581-587.
35. Srivastava, P.K., and M. Heike. 1991. Tumor-specific immunogenicity of stress-induced proteins: convergence of two evolutionary pathways of antigen presentation? Semin. Immunol. 3:57-64.
36. Sotomayor, E.M., I. Borrello, F.M. Rattis, A.G. Cuenca, J. Abrams, K. Staveley-O'Carroll, and H.I. Levitsky. 2001. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood. 98:1070-1077.
37. Yewdell, J.W., and J.R. Bennink. 1999. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17:51-88.
38. Spiotto, M.T., Y.X. Fu, and H. Schreiber. 2003. Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. Curr. Opin. Immunol. 15:725-730.
39. Medzhitov, R., and C.A. Janeway Jr. 1999. Innate immune induction of the adaptive immune response. Cold Spring Harb. Symp. Quant. Biol. 64:429-435.
40. Lyman, M.A., S. Aung, J.A. Biggs, and L.A. Sherman. 2004. A spontaneously arising pancreatic tumor does not promote the differentiation of naive CD8(+) T lymphocytes into effector CTL. J. Immunol. 172:6558-6567.
41. Huang, C.T., D.L. Huso, Z. Lu, T. Wang, G. Zhou, E.P. Kennedy, C.G. Drake, D.J. Morgan, L.A. Sherman, A.D. Higgins, et al. 2003. CD4+ T cells pass through an effector phase during the process of in vivo tolerance induction. J. Immunol 170:3945-3953.
42. Pape, K.A., R. Merica, A. Mondino, A. Khoruts, and M.K. Jenkins. 1998. Direct evidence that functionally impaired CD4+ T cells persist in vivo following induction of peripheral tolerance. J. Immunol. 160:4719-4729.
43. Perez, V.L., L. Van Parijs, A. Biuckians, X.X. Zheng, T.B. Strom, and A.K. Abbas. 1997. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity. 6:411-417.
44. - T cells. Tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med. 161:1122-1134.
45. Hung, K., R. Hayashi, A. Lafond-Walker, C. Lowenstein, D. Pardoll, and H. Levitsky. 1998. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188:2357-2368.
46. Mumberg, D., P.A. Monach, S. Wanderung, M. Philip, A.Y. Toledano, R.D. Schreiber, and H. Schreiber. 1999. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc. Natl. Acad. Sci. USA. 96:8633-8638.
47. Ramsdell, F., and B.J. Fowlkes. 1992. Maintenance of in vivo tolerance by persistence of antigen. Science. 257:1130-1134.
48. Redmond, W.L., J. Hernandez, and L.A. Sherman. 2003. Deletion of naive CD8 T cells requires persistent antigen and is not programmed by an initial signal from the tolerogenic APC. J. Immunol. 171:6349-6354.
49. Kreuwel, H.T., S. Aung, C. Silao, and L.A. Sherman. 2002. Memory CD8(+) T cells undergo peripheral tolerance. Immunity. 17:73-81.
50. Long, M., A.D. Higgins, M.A. Mihalyo, and A.J. Adler. 2003. Effector CD4 cell tolerization is mediated through functional inactivation and involves preferential impairment of TNF-alpha and IFN-gamma expression potentials. Cell. Immunol. 224:114-121.
51. Higgins, A.D., M.A. Mihalyo, and A.J. Adler. 2002. Effector CD4 cells are tolerized upon exposure to parenchymal self-antigen. J. Immunol. 169:3622-3629.
52. Jacob, J., and D. Baltimore. 1999. Modelling T-cell memory by genetic marking of memory T cells in vivo. Nature. 399:593-597.
53. + effector T cells. J. Exp. Med. 159:1295-1311.
54. Bursuker, I., and R.J. North. 1985. Suppression of generation of concomitant antitumor immunity by passively transferred suppressor T cells from tumor-bearing donors. Cancer Immunol. Immunother. 19:215-218.